The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.

[1]  Y. Pommier,et al.  The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. , 2000, Journal of medicinal chemistry.

[2]  I. Pollack,et al.  Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. , 1999, Cancer research.

[3]  T. Burke,et al.  Differential interactions of camptothecin lactone and carboxylate forms with human blood components. , 1994, Biochemistry.

[4]  T. Burke,et al.  Preferential binding of the carboxylate form of camptothecin by human serum albumin. , 1993, Analytical biochemistry.

[5]  T. Burke,et al.  Lipid bilayer partitioning and stability of camptothecin drugs. , 1993, Biochemistry.

[6]  F. Balis,et al.  Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. , 1993, Cancer research.

[7]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[8]  T. Burke,et al.  Liposomal stabilization of camptothecin's lactone ring , 1992 .

[9]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[10]  T. Furuta,et al.  Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. , 1990, Cancer research.

[11]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[12]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[13]  F. Traganos,et al.  Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. , 1988, Cancer research.

[14]  M. Wani,et al.  Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5'(RS)-1,5-dioxo-5'-ethyl-5'-hydroxy-2'H,5'H,6'H-6'-oxopyrano[3' ,4'- f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. , 1987, Journal of medicinal chemistry.

[15]  G. Manikumar,et al.  Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. , 1987, Journal of medicinal chemistry.

[16]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[17]  L. Li,et al.  Action of camptothecin on mammalian cells in culture. , 1972, Cancer research.

[18]  D. Kessel,et al.  Camptothecin effects on DNA synthesis in murine leukemia cells. , 1972, Biochimica et biophysica acta.

[19]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .